Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
indoximod (NLG8189)
i
Other names:
NLG8189, 1-MT, D-1MT, NSC-721782, NLG-001, NSC-721782, NLG 8189, NLG-8189, D1MT, 1-methyl-D-tryptophan
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(4)
News
Trials
Company:
Lumos Pharma
Drug class:
IDO inhibitor
Related drugs:
‹
IO102-IO103 (4)
Dual TDO/IDO Inhibitor (0)
IDO/TDO dual inhibitor (0)
IO102 (0)
mRNA-4359 (0)
NLG919 (0)
shIDO-ST (0)
IO102-IO103 (4)
Dual TDO/IDO Inhibitor (0)
IDO/TDO dual inhibitor (0)
IO102 (0)
mRNA-4359 (0)
NLG919 (0)
shIDO-ST (0)
›
Associations
(4)
News
Trials
VERI cancer hierarchy
Reset Filters
BRAF V600
Melanoma
BRAF V600
Melanoma
pembrolizumab + NLG8189
Sensitive: C2 – Inclusion Criteria
pembrolizumab + NLG8189
Sensitive
:
C2
pembrolizumab + NLG8189
Sensitive: C2 – Inclusion Criteria
pembrolizumab + NLG8189
Sensitive
:
C2
BRAF V600
Melanoma
BRAF V600
Melanoma
nivolumab + NLG8189
Sensitive: C2 – Inclusion Criteria
nivolumab + NLG8189
Sensitive
:
C2
nivolumab + NLG8189
Sensitive: C2 – Inclusion Criteria
nivolumab + NLG8189
Sensitive
:
C2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
NLG8189
Resistant: C3 – Early Trials
NLG8189
Resistant
:
C3
NLG8189
Resistant: C3 – Early Trials
NLG8189
Resistant
:
C3
PD-L1 expression
Melanoma
PD-L1 expression
Melanoma
pembrolizumab + NLG8189
Sensitive: C3 – Early Trials
pembrolizumab + NLG8189
Sensitive
:
C3
pembrolizumab + NLG8189
Sensitive: C3 – Early Trials
pembrolizumab + NLG8189
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login